Lb Pharmaceuticals (LBRX) Operating Leases (2024 - 2026)

Lb Pharmaceuticals' Operating Leases history runs 3 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• In Q1 2026, Operating Leases changed N/A year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $2.7 million (changed N/A YoY), while the FY2025 annual figure was $2.8 million, down 11.72% from the prior year.
• Operating Leases for Q1 2026 stood at $2.7 million, down from $2.8 million in the prior quarter.
• The five-year high for Operating Leases was $3.2 million in Q4 2024, with the low at $2.7 million in Q1 2026.
• The 3-year median for Operating Leases is $2.9 million (2025), against an average of $2.9 million.
• Peak annual rise in Operating Leases reached 11.72% in 2025, while the deepest fall reached 11.72% in 2025.
• Lb Pharmaceuticals' Operating Leases stood at $3.2 million in 2024, then declined by 11.72% to $2.8 million in 2025, then declined by 3.49% to $2.7 million in 2026.
• Business Quant data shows LBRX's Operating Leases at $2.7 million in Q1 2026, $2.8 million in Q4 2025, and $2.9 million in Q3 2025.